Shares of NewLink Genetics Corporation (NASDAQ:NLNK) last traded at $6.24. (NASDAQ:NLNK) performance year to date is -39.30%. The 200 day simple moving average is -56.19%. The 200 SMA is considered a major indicator by market analysts and traders for determining the long-term trend. The price in the market that coincides with the 200 day SMA is recognized as a key support when price moves above the 200 day SMA or resistance when price drops below the same.
NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa.
NewLink Genetics Corporation (NASDAQ:NLNK) has been in the buzz for all the right reasons.
The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend. The market is in highly oversold territory. Beware of a trend reversal.
The Exponential Moving Average is similar to a simple moving average but it uses a weighting element that exponentially drops from the recent data point. EMA analysis assesses the short term,5 days and 13 days, intermediate term that is 20 days and long-term 50 days EMA. These EMAs will give bullish indications when moving above trailing EMAs and below the latest price and vice versa. EMA alerts comprise crossovers that is the 5 day EMA crosses below/above the 20 day EMA and EMA convergences, 5 day EMA comparable to 13 day EMA. The 5 day EMA 9.77 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 15.35 is also higher than the current trading price depicting a bearish trend overall..
The relative strength index is a momentum oscillator that can measure the magnitude of stock price and velocity changes. Momentum is computed as the ratio of plus price changes to negative price changes. The RSI assessment compares the prevailing RSI against oversold (30), overbought (70) and neutral (50) conditions. Alerts will apprise you when stocks retreat from overbought/oversold levels or breakthrough neutral (50). The current RSI is 12.59 suggesting a bearish price action.
NewLink Genetics Corporation (NASDAQ:NLNK) is all set to report its earnings on May 04/b. As per Zack’s analyst scores, NewLink Genetics Corporation (NASDAQ:NLNK) currently has a mean brokerage rating of 1.4. On a scale of 1-5, a rating of 1 or 2 would imply a buy, and a rating of 4 or 5 would indicate a sell recommendation. A rating of 3 would represent a hold on the equity. The consensus target price on (NASDAQ:NLNK) is $26.8 with a high of $32 and a low of $18.
As such, while we consider NewLink Genetics Corporation (NASDAQ:NLNK) represents a enthralling growth story open to several attractive markets, it would be fascinating to see how it works for long-term shareholders.
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that on June 6, 2017, Genentech, a member of the Roche Group, informed NewLink Genetics that it intends to return the rights to IDO inhibitor GDC-0919 (navoximod) pursuant to the License Agreement dated October 16, 2014. As a consequence of such decision and pursuant to the terms of the agreement, the rights that NewLink Genetics had licensed to Genentech with respect to GDC-0919 will revert to NewLink Genetics when the termination becomes effective. The research collaboration with Genentech for the discovery of next generation IDO/TDO (tryptophan 2,3-dioxygenase) inhibitors continues.